Smoking is one of the most important cardiovascular risk factors. Varenicline, a partial agonist of the α ₄β ₂ nicotinic acetylcholine receptor, has been demonstrated to be the most efficacious medication for smoking cessation. However, treatment with varenicline has sometimes been associated with severe cardiovascular side effects. This article discusses the current data with respect to the cardiovascular safety of varenicline therapy.